Even a big trial can’t tell your whole story.
Semaglutide gives us human results to work with. That’s a useful change from trying to guess a human benefit from an animal experiment. An average still isn’t a forecast with your name on it.
We follow three findings here: the average change, how many people reached a goal, and what happened after treatment stopped. Each answers a different question.
Who was in the average
The trial enrolled adults with obesity, or overweight and a weight-related condition, without diabetes. Researchers compared a once-weekly semaglutide injection with placebo, a dummy treatment without the active medicine. Both groups also had lifestyle support. These results describe that trial preparation and setting; they don’t establish how a compounded version performs.
The average came from adults, with their own bodies and histories. The people pictured here are illustrations, not members of the semaglutide trial.
Across 68 weeks, the semaglutide group averaged a loss of roughly 15% of starting weight; placebo averaged around 2%. Those are rounded figures for change from starting weight. They describe these groups in this setting.
That’s a meaningful difference. It doesn’t mean everyone lost that amount. It also can’t tell us what would happen to someone with a different medical history.
How many reached the goal
In the same trial, about half the semaglutide group lost at least 15% of their starting weight. Now we’re counting people who crossed a line, rather than averaging everyone’s change.
That adds something useful. The average wasn’t a result everyone shared. We still don’t know each person’s experience from those two summaries, including how far above or below the line they landed.
What happened after stopping
The follow-up covered a smaller group after both the medicine and lifestyle support stopped. A year later, regain in the former semaglutide group averaged roughly two-thirds of its earlier loss. This wasn’t the whole original trial group.
That finding matters, but it isn’t an instruction to take a medicine forever. It describes what happened in that follow-up. Treatment length is a personal decision for a patient and prescriber.
The safety part belongs here too
The prescribing information lists feeling sick, vomiting, diarrhoea and constipation. Its strongest warning concerns tumours in thyroid C cells, a particular cell type, seen in rodents. We don’t know whether that rodent finding also applies to people.
The label rules out use with a personal or family history of medullary thyroid cancer, a rare thyroid cancer, or MEN 2, a rare inherited condition. Serious allergy is another exclusion. If semaglutide itself or any other ingredient has caused a serious allergic reaction before, the label says the medicine is off limits. These details need a clinician’s attention, alongside the rest of someone’s history.
FDA-approved semaglutide medicines exist. A compounded medicine is prepared for a particular patient’s medical needs. Compounded versions are not FDA-approved. A licensed U.S. clinician can discuss the appropriate options and warnings. We explain the findings without recommending a medicine.
Want to untangle another number? Read a reported range with us.